Positioning themselves as a recognized source for HER2-low breast cancer information on both the pathology and clinical standpoints, pathologists are the key drivers of increasing awareness by providing guidance and collaboration with oncologists and clinical colleagues on practice updates and resulting patient outcomes.
Hosted by the CAP Foundation and sponsored by Daiichi Sankyo, Inc. and AstraZeneca, this complimentary 60-minute live webinar will provide the pathology audience with information on HER2-low breast cancer, empowering them to be leaders and educators on this topic, increasing communication and relationships within their department, and with their oncologist partners and clinical care colleagues.
Pathologists are at the center of a patient and their diagnosis, the experts in ensuring a patient’s connection to appropriate care. HER2 is an important biomarker that can impact treatment decisions in breast cancer. Clinical data has unlocked the need to take a fresh look at the HER2 diagnostic approach. Approximately 60% of patients classified with HER2-negative breast cancer may be considered HER2-low.1 With the increasing importance of identifying HER2-low tumors, practice changes may be needed for pathologists and clinical care teams.
The 1-hour webinar will consist of live presentation only; registration is required.
Webinar attendees to gain an understanding of the importance of working directly with the clinical care team in the following ways:
- Appreciating the pathologist’s role in driving practice change
- Understanding the value of establishing multi-channel communication streams
- Understanding the need to communicate updates/information on HER2-low breast cancer to elevate clinical practice
- Feeling empowered to educate on HER2-low breast cancer
1. Tarantino P, et al. J Clin Oncol 2020;38(17):1951–1962.
Carey Z. August, MD, FCAP
Retired Chair of Pathology and Laboratory Medical Director
Advocate Illinois Masonic Medical Center
Michelle Shiller, DO, MGP, FCAP
Medical Director Cancer Genetics Baylor Sammons Cancer Center
Medical Director Genomics and Molecular Pathology Services PathGroup
This webinar is sponsored by Daiichi Sankyo, Inc. and AstraZeneca. The CAP Foundation does not endorse or promote any specific products, services, or commercial entities that may be discussed or presented during the webinar. The views, opinions, and recommendations expressed by the speakers, presenters, or any other individuals involved in the webinar are solely their own and do not represent the official stance of the CAP Foundation. This webinar is not CME accredited and participation in this webinar does not qualify for CME credits. The speakers are receiving compensation for this presentation from Daiichi Sankyo, Inc. and AstraZeneca.
HER2, human epidermal growth factor receptor 2
©2023 Daiichi Sankyo, Inc. and AstraZeneca. All rights reserved. PP-US-8201a-1740 08/23